These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study. Gudmundsdottir H; Möller PH; Jonasson JG; Björnsson ES Scand J Gastroenterol; 2019 Jan; 54(1):69-75. PubMed ID: 30638086 [TBL] [Abstract][Full Text] [Related]
24. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database. Zhang Z; Zhao X; Li Z; Wu Y; Liu Y; Li Z; Li G BMC Cancer; 2021 May; 21(1):567. PubMed ID: 34006241 [TBL] [Abstract][Full Text] [Related]
25. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Anthony LB; Strosberg JR; Klimstra DS; Maples WJ; O'Dorisio TM; Warner RR; Wiseman GA; Benson AB; Pommier RF; Pancreas; 2010 Aug; 39(6):767-74. PubMed ID: 20664474 [TBL] [Abstract][Full Text] [Related]
26. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis. Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963 [TBL] [Abstract][Full Text] [Related]
27. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population-based study. Zhong Q; Chen QY; Xie JW; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Li P; Zheng CH; Huang CM Cancer Med; 2018 Jul; 7(7):3521-3533. PubMed ID: 29873204 [TBL] [Abstract][Full Text] [Related]
28. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Chang JS; Chen LT; Shan YS; Chu PY; Tsai CR; Tsai HJ Sci Rep; 2021 Apr; 11(1):7881. PubMed ID: 33846396 [TBL] [Abstract][Full Text] [Related]
29. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours. Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105 [TBL] [Abstract][Full Text] [Related]
30. Rectal NETs and rectosigmoid junction NETs may need to be treated differently. Cai W; Ge W; Hu H; Mao J Cancer Med; 2020 Feb; 9(3):971-979. PubMed ID: 31840409 [TBL] [Abstract][Full Text] [Related]
31. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156 [TBL] [Abstract][Full Text] [Related]
32. A 5-decade analysis of 13,715 carcinoid tumors. Modlin IM; Lye KD; Kidd M Cancer; 2003 Feb; 97(4):934-59. PubMed ID: 12569593 [TBL] [Abstract][Full Text] [Related]
33. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cai W; Tan Y; Ge W; Ding K; Hu H Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523 [TBL] [Abstract][Full Text] [Related]
34. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Hassan MM; Phan A; Li D; Dagohoy CG; Leary C; Yao JC Int J Cancer; 2008 Aug; 123(4):867-73. PubMed ID: 18491401 [TBL] [Abstract][Full Text] [Related]
35. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival. Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111 [TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? McCarthy DM Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924 [TBL] [Abstract][Full Text] [Related]
37. Management of early gastrointestinal neuroendocrine neoplasms. Scherübl H; Jensen RT; Cadiot G; Stölzel U; Klöppel G World J Gastrointest Endosc; 2011 Jul; 3(7):133-9. PubMed ID: 21860682 [TBL] [Abstract][Full Text] [Related]
38. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. Sackstein PE; O'Neil DS; Neugut AI; Chabot J; Fojo T Semin Oncol; 2018 Aug; 45(4):249-258. PubMed ID: 30348533 [TBL] [Abstract][Full Text] [Related]
39. Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade. Kooyker AI; Verbeek WH; van den Berg JG; Tesselaar ME; van Leerdam ME United European Gastroenterol J; 2020 Feb; 8(1):59-67. PubMed ID: 32213058 [TBL] [Abstract][Full Text] [Related]
40. Factors Affecting Survival Outcomes in Neuroendocrine Tumor of the Appendix over the Past Two Decades. Nagesh VK; Aguilar IK; Elias D; Mansour C; Tran HH; Bhuju R; Sethi T; Sanjeeva PRP; Rivas MG; Martinez E; Auda A; Ahmed N; Philip S; Weissman S; Sotiriadis J; Bangolo A Diseases; 2024 May; 12(5):. PubMed ID: 38785751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]